ARTICLE | Finance

New WaVe of nucleic acids

Why investors are betting $18M on WaVe's stereopure nucleic acids

February 9, 2015 8:00 AM UTC

WaVe Life Sciences Pte. Ltd. and its series A investors are betting chirality matters for nucleic acid therapeutics. By YE16, the company hopes to move at least one candidate from its pipeline of stereopure compounds into the clinic.

WaVe emerged from stealth mode last week with the close of an $18 million series A round from RA Capital Management and Kagoshima Shinsangyo Sosei Investment, a large commercial development bank in Japan. Existing investor Shin Nippon Biomedical Laboratories (SNBL) Ltd. (Tokyo:2395) also participated. ...